Low Dose Iron Chelation as TReatment of Oxidative Damage in Patients With Sickle Cell Disease: the TROS Study
Latest Information Update: 15 Feb 2023
At a glance
- Drugs Deferasirox (Primary)
- Indications Sickle cell anaemia
- Focus Adverse reactions; Therapeutic Use
- Acronyms TROS study
- 09 Feb 2023 Status changed from recruiting to completed.
- 17 Mar 2021 New trial record